MNPRMonopar Therapeutics Inc.
$83.72-15% 1Y
$83.72
$50.1252 weeks$124.25
MNPR as reported
Monopar Therapeutics Inc. reported $366K of revenue over the trailing twelve months. 7 reported series are charted on this page, each one as filed.
$366K
Revenue, trailing twelve months · to Q2 2024 · every figure below is as filed, with no scoring applied
- Net income
- −$18M
Net income · +3.1% year on year · trailing twelve months to Q2 2026
Details›
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $366K | n/a | Q2 2024 · 8 quarters behind |
| Net income | −$18M | +3.1% | Q2 2026 |
| EPS | −$3.85 | n/a | Q1 2022 · 17 quarters behind |
| Operating margin | −2080% | n/a | Q2 2024 · 8 quarters behind |
| Net margin | −1980% | n/a | Q2 2024 · 8 quarters behind |
| ROE | −12% | n/a | Q2 2026 |
| ROA | −12% | n/a | Q2 2026 |
Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.
Monopar Therapeutics Inc. (MNPR) · Revenue and profitRevenue and profitMonopar Therapeutics Inc. (MNPR)
RevenueNet incomeTrailing twelve months
Powered byryufin.com
